Torrent Pharmaceuticals Share News - Latest Updates, Live News & More

Latest news about Torrent Pharmaceuticals

Torrent Pharmaceuticals Partially Redeems ₹100 Crore Non-Convertible Debentures 1 day ago Yesterday

Torrent Pharmaceuticals has partially redeemed ₹100 crore of its Secured Redeemable Non-Convertible Debentures (NCDs) before the due date of November 7, 2025. This redemption represents 20% of the total ₹500 crore NCD issue with ISIN INE685A07124. The company has informed both BSE and NSE about this financial transaction, adhering to regulatory requirements.

Torrent Pharmaceuticals Reports Strong Q2 Results with Higher EBITDA and Margin Growth 1 day ago

Torrent Pharma Set for Rs 14,000 Crore Bond Issue Following Acquisition Approval Oct 23, 2025

CCI Greenlights Torrent Pharma's Rs 19,500 Crore Acquisition of JB Chemicals Oct 23, 2025

CCI Greenlights Torrent Pharma's ₹19,500 Crore Acquisition of JB Chemicals Oct 21, 2025

More news about Torrent Pharmaceuticals

16Oct 25

Torrent Pharma Plans ₹14,000 Crore Bond Sale for JB Chemicals Acquisition

Torrent Pharmaceuticals is preparing a ₹14,000 crore bond sale to fund its acquisition of JB Chemicals & Pharmaceuticals. The company is in talks with international banks for non-convertible debentures with an expected AA+ rating and interest rate of about 7.5%. The acquisition involves purchasing a 48.8% stake from KKR and employees for ₹12,532 crore, with an additional open offer for up to 26% of public shares at ₹1,639.18 per share. Post-acquisition, Torrent plans to merge JB Chemicals at a ratio of 51 Torrent shares for every 100 JB Chemicals shares, pending regulatory approvals.

09Oct 25

CCI Raises Red Flags Over JB Chemicals and Torrent Pharma Agreement

The Competition Commission of India (CCI) has expressed concerns about an agreement between JB Chemicals and Torrent Pharmaceuticals, two major players in the Indian pharmaceutical industry. The antitrust watchdog's involvement suggests potential competition-related issues arising from the arrangement. While specific details of the agreement are not disclosed, the CCI's scrutiny indicates possible implications for fair competition in the pharmaceutical market. Both companies may need to address the issues raised by providing additional information or modifying the agreement terms. This development could have significant implications for the companies and the broader pharmaceutical industry in India.

24Sept 25

Torrent Pharmaceuticals Issues ₹200 Crore Commercial Papers with 5.93% Interest Rate

Torrent Pharmaceuticals has announced the issuance of Commercial Papers worth ₹200 crore with a 90-day tenure and 5.93% per annum interest rate. The CPs will be allotted on September 24, 2025, and mature on December 23, 2025. They are unsecured and proposed to be listed on the National Stock Exchange of India. Additionally, Torrent received approval from the Competition Commission of South Africa for acquiring a controlling stake in J. B. Chemicals & Pharmaceuticals on September 22, 2025.

23Sept 25

Torrent Pharmaceuticals Secures South African Regulatory Approval for J.B. Chemicals Acquisition

Torrent Pharmaceuticals has received approval from the Competition Commission of South Africa for its planned acquisition of a controlling stake in J.B. Chemicals & Pharmaceuticals from KKR. The approval was granted on September 22, following the initial announcement of the acquisition on June 29. Torrent Pharmaceuticals has assured that it will maintain fair and consistent relationships with all customers. This acquisition is expected to strengthen Torrent's market position and expand its product portfolio, though it may still be subject to other regulatory clearances and closing conditions.

18Sept 25

Torrent Pharmaceuticals Redeems ₹200 Crore Commercial Papers on Maturity

Torrent Pharmaceuticals has successfully redeemed Commercial Papers worth ₹200 crores on their maturity date of September 18, 2025. The CPs, issued under ISIN: INE685A14146, were originally allotted on September 17, 2025, with a 90-day tenure and a 5.93% per annum coupon rate. This timely redemption demonstrates the company's strong liquidity management and commitment to meeting financial obligations.

17Sept 25

Torrent Pharma Issues Commercial Papers Worth ₹200 Crore

Torrent Pharmaceuticals Limited has announced the issuance of commercial papers valued at ₹200.00 crore. Commercial papers are unsecured, short-term debt instruments with maturity periods up to one year. This move suggests the company is managing its liquidity, maintaining operational flexibility, and leveraging short-term financing options for working capital needs. The successful issuance may indicate market confidence in Torrent Pharmaceuticals' financial stability.

16Sept 25

Novartis Loses Patent for Cardiac Drug Vymada in India, Generic Versions to Enter Market

The Indian Patent Office has cancelled Novartis' patent for its cardiac drug Vymada (Entresto), allowing generic manufacturers to produce and distribute the medication in India. This decision is expected to increase accessibility and potentially reduce costs for heart patients. Vymada, known generically as sacubitril/valsartan, is used to treat certain types of heart failure. The ruling aligns with India's efforts to balance patent protection with public health interests. Novartis has not yet commented on potential appeals or the impact on its operations in India.

10Sept 25

Torrent Pharma Invests in Green Energy: Acquires 26% Stake in Torrent Urja 27

Torrent Pharmaceuticals is investing ₹7.92 crore to acquire a 26% stake in Torrent Urja 27 Private Limited. The investment is for a captive hybrid solar and wind power project in Gujarat, aiming to enhance the company's renewable energy portfolio. The acquisition, involving 79,19,340 Class A Equity Shares, is expected to be completed within 18 to 20 months. This move aligns with Indian electricity laws for captive power consumption and demonstrates Torrent Pharma's commitment to sustainability and operational efficiency.

02Aug 25

Torrent Pharmaceuticals' Vizag Facility Aces USFDA Inspection

Torrent Pharmaceuticals announced that its manufacturing facility in Vizag, Andhra Pradesh, successfully passed a USFDA inspection with zero observations. The inspection, conducted from July 28 to August 1, validates the company's adherence to high-quality manufacturing standards and strengthens its position in the US pharmaceutical market. This outcome may facilitate smoother approvals for future drug applications.

29Jul 25

Torrent Pharmaceuticals Shareholders Approve All Resolutions at 52nd AGM, Appoint Aman Mehta as Managing Director

Torrent Pharmaceuticals held its 52nd AGM on July 28, 2025, via video conferencing. Shareholders approved all 12 resolutions, including the appointment of Aman Mehta as Managing Director, adoption of financial statements, dividend declarations, and enhancement of borrowing limits to ₹26,000.00 crore. The meeting also saw approval for issuing equity shares and convertible bonds/debentures, indicating potential growth strategies. Strong shareholder support across all resolutions reflects confidence in the company's direction.

29Jul 25

Torrent Pharma Reports 20% Profit Growth in Q1, Driven by Strong Performance Across Key Markets

Torrent Pharmaceuticals Limited announced robust Q1 financial results with 11% revenue growth to Rs 3,178.00 crore and 20% increase in net profit to Rs 548.00 crore. The company showed strong performance across key markets: India revenues up 11%, Brazil revenues up 11%, Germany revenues up 9%, and US revenues up 19%. Operating EBITDA grew by 14% to Rs 1,032.00 crore with improved EBITDA margin of 32.50%. R&D spend increased by 16% to Rs 157.00 crore. The company maintains its position as the 7th ranked in the Indian Pharmaceutical Market.

29Jul 25

Torrent Pharma Reports 20% Net Profit Growth in Q1 FY26, Driven by Strong Performance Across Key Markets

Torrent Pharmaceuticals announced robust Q1 FY26 financial results, with revenue increasing 11% to Rs. 3,178.00 crores and net profit rising 20% to Rs. 548.00 crores. The company outperformed market growth in India and Brazil, with India revenues up 11% to Rs. 1,811.00 crores and Brazil revenues growing 11% to Rs. 218.00 crores. Germany revenues increased 9% to Rs. 308.00 crores, while US revenues surged 19% to Rs. 308.00 crores. R&D spend increased 16% to Rs. 157.00 crores, representing 5% of total revenues. The company's focus on chronic therapies and strategic launches has contributed to its strong performance across key markets.

28Jul 25

Torrent Pharma Reports 20% Net Profit Growth in Q1, Driven by Strong Performance Across Markets

Torrent Pharmaceuticals announced robust Q1 financial results with revenue reaching Rs. 3,178.00 crores, up 11% year-on-year. Operating EBITDA increased by 14% to Rs. 1,032.00 crores, while net profit after tax surged by 20% to Rs. 548.00 crores. The company saw growth across key markets: India (11%), Brazil (11%), Germany (9%), and the US (19%). R&D spend increased by 16% to Rs. 157.00 crores, accounting for 5% of total revenues. Torrent maintains a strong position in the Indian pharmaceutical market, ranking 7th overall and among the Top 5 in key therapeutic segments.

28Jul 25

Torrent Pharmaceuticals Reports Strong Q1 Results, Appoints Aman Mehta as Managing Director

Torrent Pharmaceuticals announced robust Q1 financial results with 11% revenue growth to Rs. 3,178.00 crores, 14% increase in Operating EBITDA to Rs. 1,032.00 crores, and 20% growth in net profit to Rs. 548.00 crores. The company showed growth across major markets including India, Brazil, Germany, and the United States. Shareholders approved the appointment of Aman Mehta as Managing Director for a 5-year term starting August 1, 2025. Mehta, with over 10 years of leadership experience in Torrent's Power and Pharma divisions, has a track record of expanding field force, improving portfolio performance, and successfully integrating acquisitions.

28Jul 25

Torrent Pharma Reports 20% Profit Growth in Q1; Appoints Aman Mehta as Managing Director

Torrent Pharmaceuticals reported a 20% increase in net profit to Rs 548.00 crore and an 11% rise in revenue to Rs 3,178.00 crore for Q1. The company outperformed in key markets, with India revenues growing 11% to Rs 1,811.00 crore and US revenues increasing 19% to Rs 308.00 crore. Shareholders approved Aman Mehta as Managing Director for a 5-year term starting August 1, 2025. Additionally, Torrent announced plans to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals Limited.

28Jul 25

Torrent Pharma Reports 20% Net Profit Growth in Q1, Driven by Strong Performance Across Key Markets

Torrent Pharmaceuticals announced robust Q1 financial results. Revenue increased 11% to Rs. 3,178.00 crores, operating EBITDA grew 14% to Rs. 1,032.00 crores, and net profit surged 20% to Rs. 548.00 crores. The company showed strong performance across markets: India revenues rose 11%, Brazil 11%, Germany 9%, and US 19%. R&D spend increased 16% to Rs. 157.00 crores. Torrent also entered an agreement to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals Limited, subject to approvals.

28Jul 25

Torrent Pharma Reports 20% Net Profit Growth in Q1, Driven by Strong Performance Across Key Markets

Torrent Pharmaceuticals announced robust Q1 financial results with revenue from operations increasing by 11% to Rs. 3,178.00 crores. Operating EBITDA grew by 14% to Rs. 1,032.00 crores, and net profit after tax surged by 20% to Rs. 548.00 crores. The company showed strong performance across key markets, with India revenues rising by 11% to Rs. 1,811.00 crores. International markets also reported solid growth, with Brazil, Germany, and the United States showing revenue increases. Torrent Pharma maintained a stable gross margin of 76% and increased R&D spending by 16% to Rs. 157.00 crores. The company has strengthened its position in key therapeutic segments and expanded its global presence across 50 countries.

22Jul 25

Torrent Pharmaceuticals Sees Rs. 51.64 Crore Block Trade on NSE; Announces Upcoming Financial Results

Torrent Pharmaceuticals executed a block trade of approximately 148,146 shares at Rs. 3,486.00 per share, totaling Rs. 51.64 crore on NSE. The company scheduled a board meeting for July 28 to approve Q1 financial results and consider issuing debentures/bonds. An investor conference call is set for the same day at 6:30 PM to discuss the quarter's performance.

21Jul 25

Torrent Pharmaceuticals to Discuss Private Debenture or Bond Issuance

Torrent Pharmaceuticals Limited has announced a board meeting on July 28, 2025, to discuss the private issuance of debentures or bonds, alongside reviewing financial results for the quarter ended June 30, 2025. The company will consider both unsecured and secured redeemable non-convertible debentures/bonds through private placement, indicating a potential move towards debt financing. The meeting will also address the approval of standalone audited financial results and review of consolidated unaudited financial results for the quarter.

08Jul 25

Torrent Pharmaceuticals: Significant Block Trade of Rs. 111.55 Crores on NSE

A substantial block trade of Torrent Pharmaceuticals shares occurred on the National Stock Exchange (NSE). The transaction involved approximately 335,372 shares at Rs. 3,326.10 per share, totaling Rs. 111.55 crores. This large-scale trade may indicate institutional interest or significant shareholder movements, potentially impacting the stock's liquidity and investor sentiment.

04Jul 25

Torrent Pharma Expands Stake in JB Chemicals with ₹620 Crore Deal

Torrent Pharmaceuticals has signed an agreement to acquire an additional 2.41% stake in JB Chemicals for ₹620 crore, at ₹1,600 per share. This follows a recent acquisition of a 46.39% controlling stake in JB Chemicals for ₹11,917 crore. The move is part of Torrent's strategy to fully integrate JB Chemicals, with plans for a merger post-acquisition. This acquisition is expected to strengthen Torrent's market position, create operational synergies, and potentially enhance shareholder value.

04Jul 25

Torrent Pharma Boosts Stake in JB Chemicals with ₹620 Crore Deal

Torrent Pharmaceuticals Ltd. has agreed to acquire an additional 2.41% stake in JB Chemicals & Pharmaceuticals Ltd. for ₹620 crore, valuing JB Chemicals' shares at ₹1,600 each. This follows Torrent's recent acquisition of a 46.39% controlling stake in JB Chemicals for ₹11,917 crore. Torrent plans to merge JB Chemicals into its operations post-acquisition, aiming to create synergies and strengthen its market position in the pharmaceutical industry.

04Jul 25

Torrent Pharma Expands Stake in JB Chemicals with ₹620 Crore Deal

Torrent Pharmaceuticals has signed an agreement to acquire an additional 2.41% stake in JB Chemicals for ₹620 crore, at ₹1,600 per share. This follows a recent acquisition of a 46.39% controlling stake for ₹11,917 crore. The move is part of Torrent's strategy to fully integrate JB Chemicals, with plans for a merger post-acquisition. This acquisition aims to expand Torrent's market presence, create operational synergies, and enhance its competitive position in the pharmaceutical industry.

01Jul 25

Torrent Pharma's Target Price Upgraded by BofA Securities on JB Pharma Acquisition Synergies

BofA Securities has increased Torrent Pharmaceuticals' target price to Rs 3,500.00 from Rs 3,300.00 after its acquisition of JB Pharma. The upgrade is based on expected margin synergies of 250-300 basis points by FY27-28. The merger is anticipated to positively impact earnings per share from the first year post-completion, strengthening Torrent's position in the domestic pharmaceutical market.

30Jun 25

Torrent Pharmaceuticals Set to Acquire JB Chemicals in ₹19,500 Crore Deal

Torrent Pharmaceuticals plans to acquire JB Chemicals and Pharmaceuticals in a ₹19,500 crore deal over 15-18 months. The acquisition will be executed in stages: purchasing a 46.39% stake from JB Chemicals' promoter, acquiring 2.80% from employees, and making a mandatory open offer for up to 26% from public shareholders. Post-acquisition, JB Chemicals is expected to merge into Torrent Pharmaceuticals, potentially strengthening Torrent's market position.

21May 25

Torrent Pharma Q4 Results Meet Expectations, Analysts Remain Optimistic

Torrent Pharmaceuticals' Q4 results met market expectations with improved profitability. The company reported an adjusted EBITDA margin of 33.20%, up 60 basis points quarter-on-quarter. Strong growth was seen in both Indian and US markets. Citi maintained a positive outlook with a price target of ₹4,000.00. Torrent plans to add 1,200 new sales personnel over FY2024-2026.

20May 25

Torrent Pharmaceuticals: Q4 Profit Up 11%, Plans Rs 5,000-Crore Fundraise

Torrent Pharmaceuticals announced Q4 results with an 11% increase in net profit to ₹498 crore and a 7.8% rise in revenue to ₹2,959 crore. The company declared a final dividend of ₹6 per share and is seeking approval for a ₹5,000 crore share issuance. The board recommended Aman Mehta for the role of Managing Director.

13May 25

Torrent Pharma to Explore Fundraising Options in Upcoming Board Meeting

Torrent Pharmaceuticals has announced a board meeting scheduled for May 20 to discuss and consider potential fundraising options. This development suggests the company may be exploring ways to secure additional capital, which could be used for expansion, R&D, debt reduction, or acquisitions. The outcome of this meeting will be closely watched by investors and market analysts as it could provide insights into the company's financial strategy and future growth plans.

27Mar 25

Torrent Pharmaceuticals Raises ₹200 Crore Through Commercial Paper Issuance

Torrent Pharmaceuticals Limited has successfully raised ₹200 crore through the issuance of commercial papers with a 93-day tenure. The papers, set to mature on June 27, 2025, carry a coupon rate of 7.13% per annum and are proposed to be listed on the National Stock Exchange of India. This unsecured short-term debt instrument issuance demonstrates the company's strong market position and ability to access cost-effective funding for operational needs.

26Mar 25

Torrent Pharmaceuticals Raises ₹200 Crore Through Commercial Paper Issue

Torrent Pharmaceuticals has issued commercial papers worth ₹200 crore with a 93-day tenure at 7.13% per annum. The papers, set to mature on June 27, 2025, are unsecured and proposed for listing on NSE. Simultaneously, the company announced full redemption of a previous ₹200 crore commercial paper issuance, demonstrating active short-term debt management.

25Mar 25

Torrent Pharmaceuticals Raises ₹300 Crore Through Commercial Paper Issue

Torrent Pharmaceuticals has issued commercial papers worth ₹300 crore with a 90-day tenure. The papers, allotted on March 25, 2025, will mature on June 23, 2025, carrying a 7.13% per annum coupon rate. They are unsecured and proposed to be listed on the National Stock Exchange of India. This move demonstrates the company's strong financial position and efficient access to capital markets, potentially aimed at optimizing cash management or funding short-term operational needs.

10Mar 25

Torrent Pharma to Launch Affordable Diabetes Medication, Boosting Treatment Accessibility

Torrent Pharmaceuticals Ltd is planning to introduce an affordable version of empagliflozin, a vital medication for type 2 diabetes. This move is part of a broader initiative by Indian pharmaceutical companies to improve access to essential medications. The launch of low-cost empagliflozin is expected to enhance accessibility for a larger diabetic population, potentially reshape the diabetes care market in India, and increase competition while reducing overall treatment costs.

28Feb 25

Torrent Pharma Set for $43 Million Inflow as MSCI India Index Weightage Increases

Torrent Pharmaceuticals' weightage in the MSCI India Standard Index is set to increase, potentially triggering a $43 million (Rs 3.76 billion) inflow into the stock. This adjustment, effective today at 3 PM, is expected to boost liquidity and attract more passive funds and index-tracking investors. Separately, Pranav Mehta, Executive Director (Strategic Planning), has resigned effective February 26, 2025, to pursue new career opportunities.